Abstract
Since the introduction of several novel agents with different mechanisms of action in the past decade, inhibitors of the epidermal growth factor receptor (EGFR) have increased therapeutic options for patients with metastatic colorectal cancer (mCRC) requiring treatment following chemotherapy failure. Seront et al. report the noteworthy case of a patient with mCRC and wild-type KRAS status, who had progressed during two lines of standard irinotecan-based (FOLFIRI) and oxaliplatin-based (FOLFOX) chemotherapy prior to receiving the EGFR inhibitor panitumumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
